148 related articles for article (PubMed ID: 19348043)
1. Wnt therapy for bone loss: golden goose or Trojan horse?
Enders GH
J Clin Invest; 2009 Apr; 119(4):758-60. PubMed ID: 19348043
[TBL] [Abstract][Full Text] [Related]
2. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice.
Kansara M; Tsang M; Kodjabachian L; Sims NA; Trivett MK; Ehrich M; Dobrovic A; Slavin J; Choong PF; Simmons PJ; Dawid IB; Thomas DM
J Clin Invest; 2009 Apr; 119(4):837-51. PubMed ID: 19307728
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.
Aguilera O; Fraga MF; Ballestar E; Paz MF; Herranz M; Espada J; García JM; Muñoz A; Esteller M; González-Sancho JM
Oncogene; 2006 Jul; 25(29):4116-21. PubMed ID: 16491118
[TBL] [Abstract][Full Text] [Related]
4. Wnt-inhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells.
Schaniel C; Sirabella D; Qiu J; Niu X; Lemischka IR; Moore KA
Blood; 2011 Sep; 118(9):2420-9. PubMed ID: 21652676
[TBL] [Abstract][Full Text] [Related]
5. Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
Cai Y; Cai T; Chen Y
J Cell Biochem; 2014 Apr; 115(4):625-31. PubMed ID: 24190862
[TBL] [Abstract][Full Text] [Related]
6. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma.
Kongkham PN; Northcott PA; Croul SE; Smith CA; Taylor MD; Rutka JT
Oncogene; 2010 May; 29(20):3017-24. PubMed ID: 20208569
[TBL] [Abstract][Full Text] [Related]
7. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.
Rubin EM; Guo Y; Tu K; Xie J; Zi X; Hoang BH
Mol Cancer Ther; 2010 Mar; 9(3):731-41. PubMed ID: 20197388
[TBL] [Abstract][Full Text] [Related]
8. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.
Cai Y; Mohseny AB; Karperien M; Hogendoorn PC; Zhou G; Cleton-Jansen AM
J Pathol; 2010 Jan; 220(1):24-33. PubMed ID: 19882675
[TBL] [Abstract][Full Text] [Related]
9. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Hu J; Dong A; Fernandez-Ruiz V; Shan J; Kawa M; Martínez-Ansó E; Prieto J; Qian C
Cancer Res; 2009 Sep; 69(17):6951-9. PubMed ID: 19690140
[TBL] [Abstract][Full Text] [Related]
10. Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma.
Baker EK; Taylor S; Gupte A; Chalk AM; Bhattacharya S; Green AC; Martin TJ; Strbenac D; Robinson MD; Purton LE; Walkley CR
Bone; 2015 Apr; 73():223-32. PubMed ID: 25571841
[TBL] [Abstract][Full Text] [Related]
11. Wnt signaling as a therapeutic target for bone diseases.
Hoeppner LH; Secreto FJ; Westendorf JJ
Expert Opin Ther Targets; 2009 Apr; 13(4):485-96. PubMed ID: 19335070
[TBL] [Abstract][Full Text] [Related]
12. Shifted from Wnt to Hedgehog signaling pathways.
Han C; Lin X
Mol Cell; 2005 Feb; 17(3):321-2. PubMed ID: 15694333
[TBL] [Abstract][Full Text] [Related]
13. Role of Wnt inhibitory factor-1 and Wnt/wingless signaling in choroid plexus tumors.
Tomm M; Koch A; Mertsch S; Wrede B; Jeibmann A; Wolff J; Paulus W; Hasselblatt M
Pediatr Blood Cancer; 2009 Dec; 53(6):1152-5. PubMed ID: 19621428
[TBL] [Abstract][Full Text] [Related]
14. Evidence for altered Wnt signaling in psoriatic skin.
Gudjonsson JE; Johnston A; Stoll SW; Riblett MB; Xing X; Kochkodan JJ; Ding J; Nair RP; Aphale A; Voorhees JJ; Elder JT
J Invest Dermatol; 2010 Jul; 130(7):1849-59. PubMed ID: 20376066
[TBL] [Abstract][Full Text] [Related]
15. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors.
Pannone G; Bufo P; Santoro A; Franco R; Aquino G; Longo F; Botti G; Serpico R; Cafarelli B; Abbruzzese A; Caraglia M; Papagerakis S; Lo Muzio L
Oncol Rep; 2010 Oct; 24(4):1035-41. PubMed ID: 20811686
[TBL] [Abstract][Full Text] [Related]
16. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
Ramachandran I; Thavathiru E; Ramalingam S; Natarajan G; Mills WK; Benbrook DM; Zuna R; Lightfoot S; Reis A; Anant S; Queimado L
Oncogene; 2012 May; 31(22):2725-37. PubMed ID: 22002305
[TBL] [Abstract][Full Text] [Related]
17. Secreted WNT antagonists as tumor suppressors: pro and con.
Rubin JS; Barshishat-Kupper M; Feroze-Merzoug F; Xi ZF
Front Biosci; 2006 Sep; 11():2093-105. PubMed ID: 16720296
[TBL] [Abstract][Full Text] [Related]
18. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer.
Suzuki H; Toyota M; Carraway H; Gabrielson E; Ohmura T; Fujikane T; Nishikawa N; Sogabe Y; Nojima M; Sonoda T; Mori M; Hirata K; Imai K; Shinomura Y; Baylin SB; Tokino T
Br J Cancer; 2008 Mar; 98(6):1147-56. PubMed ID: 18283316
[TBL] [Abstract][Full Text] [Related]
19. Temporal control of Wnt signaling is required for habenular neuron diversity and brain asymmetry.
Guglielmi L; Bühler A; Moro E; Argenton F; Poggi L; Carl M
Development; 2020 Mar; 147(6):. PubMed ID: 32179574
[TBL] [Abstract][Full Text] [Related]
20. Silencing microRNA-27a inhibits proliferation and invasion of human osteosarcoma cells through the SFRP1-dependent Wnt/β-catenin signaling pathway.
Mu Y; Zhang L; Chen X; Chen S; Shi Y; Li J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31072914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
